Advertisement

Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae

  • A. Fenoll
  • M. J. Giménez
  • O. Robledo
  • L. Aguilar
  • D. Tarragó
  • J. J. Granizo
  • J. E. Martín-Herrero
Article

Abstract

To study the influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins, 430 consecutive penicillin non-susceptible Streptococcus pneumoniae 2007 isolates received in the Spanish Reference Pneumococcal Laboratory were tested. For comparative purposes, 625 penicillin-susceptible 2007 isolates were also tested. Susceptibility was determined by agar dilution using Mueller-Hinton agar supplemented with 5% sheep blood. Penicillin-susceptible strains were susceptible to amoxicillin, cefotaxime and ceftriaxone, 99.8% to cefpodoxime and 99.5% to cefdinir, and were inhibited by 0.12 μg/ml of cefditoren and 4 μg/ml of cefixime. Penicillin-intermediate strains were susceptible to cefotaxime and ceftriaxone, with <50% susceptibility to cefdinir and cefpodoxime. The MIC50 and MIC90 values of cefditoren were 0.25 μg/ml and 0.5 μg/ml, respectively, whereas cefixime exhibited only marginal activity (MIC90=16 μg/ml). Penicillin-resistant strains were resistant to cefdinir and cefpodoxime, with 74.8% and 94.1% susceptibility to cefotaxime and ceftriaxone, respectively. Cefditoren MIC50/MIC90 (0.5/1 μg/ml) were lower than cefotaxime and ceftriaxone. Among amoxicillin non-susceptible strains, susceptibility to cefdinir and cefpodoxime was <10%, and susceptibility to cefotaxime decreased from 87.9% in the intermediate category to 63.0% in the resistant group. Cefditoren MIC50/MIC90 (0.5/1 μg/ml) were lower than cefotaxime. In conclusion, the activity of cefixime, cefdinir and cefpodoxime was highly affected by penicillin/amoxicillin non-susceptibility, while parenteral third-generation cephalosporins exhibited higher intrinsic activity (MIC90=1 μg/ml for penicillin-resistant and 2 μg/ml for amoxicillin-resistant strains). Cefditoren exhibited one-dilution lower MIC90 values for these strains, even against those of the most troublesome serotypes.

Keywords

Amoxicillin Ceftriaxone Cefotaxime Cefixime Cefpodoxime 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported by an unrestricted grant from GlaxoSmithKline S.A., Tres Cantos, Madrid, Spain.

References

  1. 1.
    Pérez-Trallero E, Garcia-de-la-Fuente C, García-Rey C, Baquero F, Aguilar L, Dal-Ré R, García-de-Lomas J; Spanish Surveillance Group for Respiratory Pathogens (2005) Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 49:1965–1972PubMedCrossRefGoogle Scholar
  2. 2.
    Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, Bouza E, Aguilar L, García-de-Lomas J, Baquero F; Spanish Surveillance Group for Respiratory Pathogens (2001) Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998–1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 45:3334–3340PubMedCrossRefGoogle Scholar
  3. 3.
    Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E (1999) Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother 43:1480–1483PubMedGoogle Scholar
  4. 4.
    Pérez-Trallero E, Marimón JM, González A, García-Rey C, Aguilar L (2003) Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 47:3637–3639PubMedCrossRefGoogle Scholar
  5. 5.
    Pérez-Trallero E, Marimón JM, Ercibengoa M, Coronel P, Giménez MJ, Aguilar L (2007) Antimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 13:937–940PubMedCrossRefGoogle Scholar
  6. 6.
    Garau J (2005) Both penicillin and amoxycillin should be tested in antimicrobial surveillance for Streptococcus pneumoniae. Clin Microbiol Infect 11:422–423PubMedCrossRefGoogle Scholar
  7. 7.
    Prieto J, Calvo A, Gómez-Lus ML (2002) Antimicrobial resistance: a class effect?. J Antimicrob Chemother 50(Suppl S2):7–12CrossRefGoogle Scholar
  8. 8.
    Klugman KP (2002) Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 36 (Suppl):3s–8sCrossRefGoogle Scholar
  9. 9.
    Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP; International Pneumococcal Study Group (2003) An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37:230–237PubMedCrossRefGoogle Scholar
  10. 10.
    Fenoll A, Jado I, Vicioso D, Casal J (1997) Dot blot assay for the serotyping of pneumococci. J Clin Microbiol 35:764–766PubMedGoogle Scholar
  11. 11.
    Clinical and Laboratory Standards Institute (CLSI) (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7. CLSI, Wayne, PennsylvaniaGoogle Scholar
  12. 12.
    Clinical and Laboratory Standards Institute (CLSI) (2007) Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. CLSI, Wayne, PennsylvaniaGoogle Scholar
  13. 13.
    Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF (2002) In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 42:59–64PubMedCrossRefGoogle Scholar
  14. 14.
    Nagai K, Davies TA, Jacobs MR, Appelbaum PC (2002) Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 46:1273–1280PubMedCrossRefGoogle Scholar
  15. 15.
    Li JT, Hou F, Lu H, Li TY, Li H (1997) Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 23:145–150PubMedGoogle Scholar
  16. 16.
    Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN (2000) Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 37:99–105PubMedCrossRefGoogle Scholar
  17. 17.
    Jones RN, Biedenbach DJ, Croco MA, Barrett MS (1998) In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 31:573–578PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • A. Fenoll
    • 1
  • M. J. Giménez
    • 2
  • O. Robledo
    • 1
  • L. Aguilar
    • 2
  • D. Tarragó
    • 1
  • J. J. Granizo
    • 3
  • J. E. Martín-Herrero
    • 4
  1. 1.Spanish National Reference Pneumococcal LaboratoryInstituto de Salud Carlos IIIMajadahondaSpain
  2. 2.Microbiology Department, School of MedicineUniversity ComplutenseMadridSpain
  3. 3.Granadatos SLPozuelo de AlarcónSpain
  4. 4.Medical DepartmentGlaxoSmithKline S.A.Tres CantosSpain

Personalised recommendations